An April source article says FDA approval now includes TMS for adolescents 15 and older, while most insurance plans may not yet cover treatment for teens.
FDA approval described for adolescents
According to the source article, Transcranial Magnetic Stimulation, or TMS, was previously FDA-approved only for adults aged 18 and older. The article states that FDA approval has expanded to include adolescents aged 15 and up for treatment-resistant depression.
The source describes the change as an additional option for teens whose depression has not found lasting relief through medication or therapy. It also notes that FDA approval does not automatically mean that treatment will be covered by insurance.
How the source describes TMS
The source article describes TMS as a non-invasive depression treatment that uses magnetic pulses to stimulate areas of the brain involved in mood regulation. It says a small magnetic coil is placed near the scalp, allowing pulses to pass through the skull and activate targeted brain regions.
According to the article, TMS does not require anesthesia or recovery time. It says treatment is generally delivered in an outpatient setting and is presented as a drug-free alternative for some people with depression.
The article states that adolescents may have daily sessions, usually five days a week, over six to eight weeks. It says individual sessions typically last about 20 to 30 minutes and that patients can resume normal activities afterward.
Side effects and treatment access
The source article says most individuals experience minimal side effects, though some report temporary scalp tenderness, headaches, or mild discomfort at the treatment site. It describes treatment as taking place in a professional clinic setting with support for teens and their families.
According to the source, many insurance plans do not yet cover TMS for teens, which may create a barrier for families. The article says Cigna covers TMS for people ages 15 through 17 as well as adults, while noting that other insurers may or may not follow as adolescent treatment coverage develops.
The source also notes that self-pay options may be available when insurance does not cover treatment.
Teen depression context
The article cites the National Institute of Mental Health estimate that five million U.S. adolescents ages 12 through 17 experienced at least one major depressive episode in 2021. It also says adolescent mental health concerns have received greater attention since the COVID-19 pandemic.
According to the source, social isolation, academic pressures, and changes in routine have contributed to anxiety and depression among teens. The article presents the expanded FDA approval as a development relevant to families exploring depression-treatment options.
What this means for Indiana patients
Indiana families looking for local treatment information can use this directory, which lists 68 published clinics in Indiana, while checking directly on age eligibility, availability, and insurance coverage.
This is general information, not medical advice.
More Indiana reporting on treatment updates.
This report is educational and is not medical advice. Coverage, availability and eligibility can change; verify details with the named source or your care team.